Cornercap Investment Counsel Inc. Has $80,000 Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Cornercap Investment Counsel Inc. reduced its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 55.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,533 shares of the company’s stock after selling 34,937 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Allogene Therapeutics were worth $80,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ALLO. Curi RMB Capital LLC grew its stake in shares of Allogene Therapeutics by 47.5% in the 3rd quarter. Curi RMB Capital LLC now owns 149,577 shares of the company’s stock valued at $419,000 after buying an additional 48,202 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Allogene Therapeutics by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 40,219 shares of the company’s stock valued at $113,000 after acquiring an additional 15,690 shares during the last quarter. Private Advisor Group LLC bought a new stake in Allogene Therapeutics in the third quarter worth approximately $34,000. Creative Planning increased its stake in shares of Allogene Therapeutics by 108.7% during the 3rd quarter. Creative Planning now owns 61,396 shares of the company’s stock worth $172,000 after purchasing an additional 31,984 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Allogene Therapeutics by 25.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 60,675 shares of the company’s stock valued at $170,000 after purchasing an additional 12,328 shares in the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

Allogene Therapeutics Trading Down 5.3 %

ALLO opened at $2.15 on Tuesday. The business has a 50 day moving average of $2.74 and a 200-day moving average of $2.65. The stock has a market capitalization of $450.79 million, a price-to-earnings ratio of -1.38 and a beta of 0.84. Allogene Therapeutics, Inc. has a 1-year low of $2.01 and a 1-year high of $5.78.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ALLO shares. Piper Sandler decreased their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Citigroup raised their price objective on Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Oppenheimer assumed coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They set an “outperform” rating and a $11.00 target price for the company. Finally, Canaccord Genuity Group dropped their price target on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).